Dr. Geoffrey Stuart Pitt, MD

Is this you?

Claim your profile

Cardiovascular Disease Internal Medicine

Leave a review

Perkin Center For Heart Failure

520 E 70TH ST FL 4, NEW YORK, NY, 10021

6 other locations

OVERVIEW

Dr. Pitt graduated from the Johns Hopkins University School of Medicine in 1993. He works in NEW YORK, NY and 5 other locations and specializes in Cardiovascular Disease and Internal Medicine.

RATINGS AND REVIEWS

Dr. Pitt's Rating

1 Rating with 1 Review

Patient Perspective

1.0 Explains conditions and treatments

1.0 Takes time to answer my questions

1.0 Provides follow-up as needed

Office Rating

Showing ratings for:

n/a Average office wait time

n/a Office cleanliness

n/a Courteous staff

n/a Scheduling flexibility

Weill Cornell Medicine New York Presbyterian Cardiology

520 E 70TH ST FL 4

NEW YORK, NY, 10021

1 REVIEWS

Showing 1-1 of 1 review

"I discovered from a DNA test that I unfortunately am one of the unlucky individuals who have not one by two copies of a variant gene encoding a pathological form of apolipoprotein called “APOE4”. By having two copies of this variant (i.e., by being “homogenous APOE4”) I have a 1500% chance of getting Alzheimer’s Disease (“AD”). Basically, if I live long enough, I will ultimately succumb to AD much like direct family of mine have done so before my eyes. As such, I have closely followed AD clinical trials and long observed the absence of any interventions that truly alter patient outcome or prognosis. When I learned of Simufilam’s phase 2b trial data (explained in more detail below), I was for the first time provided a true glimmer of hope. I became both an expectant future patient given my genetic condition and an investor. Soon after my discovery of Simufilam, Dr. Pitt anonymously co-authored allegations regarding Simufilam under false pretenses to enable profit from a secret “short” ...

bet against the company behind the trials, Cassava Sciences, Inc. (“SAVA”). Specifically, Dr. Pitt, in the vein of a helpful “whistleblower,” sought to convince the FDA to halt late stage clinical trials of this promising and desperately needed therapeutic for his own enrichment. As his actions have so far been unsuccessful, Dr. Pitt’s attacks have become increasingly unhinged and repugnant. He has gone so far as to use a child’s weakness in the aftermath of her rape at the hands of her stepfather as a justification to halt phase 3 trials of Simufilam some 30 years later. I believe his actions constitute a willful false report and demonstrate moral unfitness to practice medicine in the state of New York as defined by Article 131-A § 6530. The public is best served by preventing the practice of medicine by individuals who would seek to destroy the one potential meaningful treatment for patients dying from an as yet incurable and fatal disease for profit – individuals like Dr. Pitt. Below, I break down the following series of events and observations on Dr. Pitt’s Actions. Dr. Pitt (along with partner Dr. Bredt): 1. Filed A Citizen’s Petition Under False Pretenses 2. Attacked an Extremely Promising and Desperately Needed Therapy 3. Appears to Have Significantly Profited From His Dishonesty 4. Extracted Such Profit Through Great Potential Harm to Patients 5. Doubled Down Upon His Failure With Reprehensible Personal Attacks 6. Appears to be Part of a Coordinated Campaign With Conflicts of Interest 1. Dr. Pitt Filed A Citizen’s Petition Under False Pretenses In August 2021, Dr. Pitt through his lawyer filed a Citizen’s Petition (“CP”) with the FDA seeking to convince the FDA to halt the upcoming Phase 3 trial of Simufilam as a therapeutic in the treatment of AD. The investment industry has a history of filing CP’s under false pretenses (which generally argue the FDA must halt a phase 3 trial due to risk of patient harm) as a way to manipulate stock price after establishing a financial position which would profit from a decrease in a company’s stock price (i.e., taking a “short” position). The infamous Martin Shkreli was a pioneer in this technique, using misleading CPs to both profit from a short bet against the market’s reaction to a CP and to weaken a company for attempted hostile takeover.1 This CP was claimed to be authored by a “whistleblower” and ostensibly pushed the FDA for the halt to protect patient safety. This stated authorship was both an outright fabrication and grossly misleading: 2 Several days and an easily predictable SAVA stock crash later, the law firm filing the CP acknowledged its client had a taken a short position in the company sponsoring Simufilam, Cassava Sciences, Inc. (“SAVA”).3 Additionally, the Wallstreet Journal later disclosed that, rather than being a whistleblower as stated, the law firm’s clients and the CP co-authors were third parties outside of SAVA, namely, Dr. Pitt "